Viatris Expands CNS Portfolio in Japan with Aculys Pharma Acquisition

miércoles, 15 de octubre de 2025, 4:31 pm ET1 min de lectura
VTRS--

Viatris has acquired Aculys Pharma, expanding its presence in Japan with the addition of two innovative assets targeting areas of significant unmet medical need. The acquisition includes exclusive rights to pitolisant and Spydia, strengthening Viatris' CNS therapy area and aligning with its strategy to target accretive regional business development opportunities.

Viatris Expands CNS Portfolio in Japan with Aculys Pharma Acquisition

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios